Cytotoxic effect of fucoidan extracted from Sargassum cinereum on colon cancer cell line HCT-15

Somasundaram, Sivasankara Narayani; Saravanan, S.; Bharathiraja, Subramaniyan; Jaganathan, Ravindran

doi:10.1016/j.ijbiomac.2016.06.084

Cited by 64 publications

(38 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to previous in vitro and animal studies, Fucoidan has a cytotoxic effect in the HCT-15 colon cancer cell line [35]. Fucoidan also inhibits the migration and proliferation of HT-29 human colon cancer cells via the phosphoinositide-3 kinase/Akt/mechanistic target of rapamycin pathways [36].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Low-Molecular-Weight Fucoidan as a Supplemental Therapy in Metastatic Colorectal Cancer Patients: A Double-Blind Randomized Controlled Trial

et al. 2017

View full text Add to dashboard Cite

Background: Low-molecular-weight fucoidan (LMF) is widely used as a food supplement for cancer patients. However, all of the studies are in vitro or were conducted using mice. Therefore, powerful clinical evidence for LMF use is relatively weak. This study aimed to evaluate the efficacy of LMF as a supplemental therapy to chemo-target agents in metastatic colorectal cancer (mCRC) patients. Methods: We conducted a prospective, randomized, double-blind, controlled trial to evaluate the efficacy of LMF as a supplemental therapy to chemotarget agents in patients with metastatic colorectal cancer (mCRC). Sixty eligible patients with mCRC were included. Finally, 54 patients were enrolled, of whom 28 were included in the study group and 26 in the control group. The primary endpoint was the disease control rate (DCR), and secondary endpoints included the overall response rate (ORR), progression-free survival (PFS), overall survival (OS), adverse effects (AEs), and quality of life (QOL). Results: The DCRs were 92.8% and 69.2% in the study and control groups, respectively (p = 0.026), in a median follow-up period of 11.5 months. The OS, PFS, ORR, AEs, and QOL did not significantly differ between the two groups. Conclusion: This is the first clinical trial evaluating the efficacy of LMF as a supplemental therapy in the management of patients with mCRC. The results indicate that LMF combined with chemotarget agents significantly improved the DCR.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of Low-Molecular-Weight Fucoidan as a Supplemental Therapy in Metastatic Colorectal Cancer Patients: A Double-Blind Randomized Controlled Trial

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Globally, the incidence of colon cancer is increasing, seemingly due to changes in dietary habits and preferences. Dietary habits can affect the development of colon cancer, and food ingredients may serve as chemotherapeutic agents (22,24,(38)(39)(40)(41)(42)(43). Many studies have investigated potential colon cancer treatments.…”

Section: Discussionmentioning

confidence: 99%

“…Numerous studies have investigated the effects of seaweeds on cell death pathways including apoptosis. The inhibition of apoptosis in colon cancer cells promotes tumor growth and tumor progression and imparts tolerance to cytotoxic anticancer drugs (7,22,23,27,(40)(41)(42)(43).…”

Section: Discussionmentioning

confidence: 99%

“…Fucoidan has been shown to exert various biological activities, including antioxidant, anti-inflammatory, anti-angiogenic, anti-coagulant, anti-bacterial, and anticancer effects (8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18). Studies have shown anticancer activities of fucoidan in lung, breast, liver, colon, prostate, and bladder cancer cells (19)(20)(21)(22)(23). Fucoidan has also been shown to induce tumor cell injury leading to growth arrest and tumor suppression via apoptosis and cell cycle arrest in various cancer cell types (24)(25)(26)(27)(28)(29).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Fucoidan downregulates insulin-like growth factor-I receptor levels in HT-29 human colon cancer cells

Kim

Nam

2018

Oncol Rep

View full text Add to dashboard Cite

Fucoidan, a sulfated polysaccharide present in brown seaweed, has demonstrated anticancer activity in lung, breast, liver and colon cells. The insulin-like growth factor (IGF) signaling pathway regulates growth in HT-29 cells through the insulin receptor substrate-1 (IRS-1)/phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) and Ras/Raf/extracellular signal-regulated kinase (ERK) pathways. The aim of the present study was to investigate whether fucoidan downregulates the IGF-IR signaling pathway in HT-29 human colon cancer cells. Fucoidan treatment (0-1,000 µg/ml) was administered for 24 h in HT-29 cells. First, we investigated IRS-1/PI3K/AKT pathway-related protein expression levels following treatment with fucoidan (0-500 µg/ml) using western blot analysis. Fucoidan significantly inhibited the expression of IGF-IR, PTEN, PI3K and AKT as well as their phosphorylated forms (p-IRS-1, p-PI3K and p-AKT). Next, we investigated the effects of fucoidan on Ras/Raf/ERK pathway‑related protein expression levels in HT-29 cells. Fucoidan significantly inhibited the expression of IGF-IR, Shc, Ras, SOS, Raf and MEK. HT-29 cells were then incubated in the presence of fucoidan (0 or 250 µg/ml), and IGF-I (10 nM) was added for 0 to 60 min. Immunoprecipitation (IP) experiments showed that fucoidan inhibited IGF-I-induced phosphorylation of IGF-IR, PI3K, Shc (IP, IGF-IR), and phosphorylated IRS-1 and PI3K (IP, IRS-1) compared to the control group. Western blot analysis showed that fucoidan inhibited the expression of IGF-I-induced p-IGF-IR/IGF-IR and p-AKT/AKT, but not p-ERK/ERK. In conclusion, the inhibition of cell viability by fucoidan in HT-29 cells may be due to the downregulation of IGF-IR signaling through the main IRS-1/PI3K/AKT pathway. Fucoidan also partially impacted Ras/Raf signaling in the Ras/Raf/ERK pathway. Therefore, we suggest that fucoidan may be a suitable candidate chemopreventive agent in HT-29 colon cancer cells.

show abstract

“…Filtration, dialysis and centrifugation, either for the algal biomass or precipitates, are also among the downstream processes after pre-treatment and extraction steps [131][132][133]. Cross-flow filtration and dialysis against water are usually performed using different molecular weight cut-off (MWCO) membranes for isolation of fucoidans from smaller compounds depending on the high molecular weight of fucoidans [134] and also for fractionation purposes, where low molecular weight fucoidans (LMWF) can be separated from high molecular weight analogues (HMWF) [49].…”

Section: Separation Physical Methodsmentioning

confidence: 99%

Fucoidans: Downstream Processes and Recent Applications

Zayed

Ulber

2020

Marine Drugs

View full text Add to dashboard Cite

Fucoidans are multifunctional marine macromolecules that are subjected to numerous and various downstream processes during their production. These processes were considered the most important abiotic factors affecting fucoidan chemical skeletons, quality, physicochemical properties, biological properties and industrial applications. Since a universal protocol for fucoidans production has not been established yet, all the currently used processes were presented and justified. The current article complements our previous articles in the fucoidans field, provides an updated overview regarding the different downstream processes, including pre-treatment, extraction, purification and enzymatic modification processes, and shows the recent non-traditional applications of fucoidans in relation to their characters. of 22reproductive, immune and cell-to-cell communicative roles [23]. As recommended by the International Union of Pure and Applied Chemistry (IUPAC), fucoidans is a general term used to describe sulfated L-fucose-based polymers including sulfated fucans cited by the Swedish scholar Kylin, as well as other fucose-rich sulfated heteropolysaccharides [23,28]. Their chemical structures, in terms of monomeric composition and branching, are quite simple in marine invertebrates compared to their analogues in brown algae [13,29].Hundreds of articles have thoroughly discussed and reviewed the biological, pharmacological and pharmaceutical applications of fucoidans [30][31][32][33], including nanomedicine, [34] which has made it a hot topic in the last few decades [35][36][37]. All these studies tried to investigate fucoidans molecular mechanisms in relation to their chemical structure and physicochemical properties. Therefore, different hypotheses were suggested for each activity, such as anti-tumor [31,[38][39][40], anti-coagulant [41,42], anti-viral [43,44] and anti-inflammatory activity [45,46]. These investigations revealed that various factors are relevant, such as molecular weight, sulfation pattern, sulfate content and monomeric composition [47][48][49]. For example, different fractions were produced with different physicochemical properties in our previous experiments; sulfation pattern and sulfate content were highly related to anti-viral and cytotoxic activities against HSV-1 and Caco-2 cell lines, respectively, while molecular weight and sugar composition were potential factors in anti-coagulation activity [41,50]. In addition, degree of purity was reported as an influential factor [32], where co-extracted contaminants (e.g., phlorotannins or polyphenols) could lead to significant interference in anti-oxidant activity and, consequently, cosmetic applications [51,52].Therefore, several key production challenges regarding fucoidans were discussed in our last review article in order to obtain a product that follows the universal good manufactured practice (GMP) guidelines. The article discussed sources of heterogeneity in extracted fucoidans, including the different biotic (e.g., biogenic, geographical and seas...

show abstract

Cytotoxic effect of fucoidan extracted from Sargassum cinereum on colon cancer cell line HCT-15

Cited by 64 publications

References 41 publications

Efficacy of Low-Molecular-Weight Fucoidan as a Supplemental Therapy in Metastatic Colorectal Cancer Patients: A Double-Blind Randomized Controlled Trial

Efficacy of Low-Molecular-Weight Fucoidan as a Supplemental Therapy in Metastatic Colorectal Cancer Patients: A Double-Blind Randomized Controlled Trial

Fucoidan downregulates insulin-like growth factor-I receptor levels in HT-29 human colon cancer cells

Fucoidans: Downstream Processes and Recent Applications

Contact Info

Product

Resources

About